Normal thymocyte negative selection in TRAIL-deficient mice

The molecular basis of thymocyte negative selection, which plays a critical role in establishing and maintaining immunological tolerance, is not yet resolved. In particular, the importance of the death receptor subgroup of the tumor necrosis factor (TNF)-family has been the subject of many investiga...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of experimental medicine Vol. 198; no. 3; pp. 491 - 496
Main Authors Cretney, Erika, Uldrich, Adam P, Berzins, Stuart P, Strasser, Andreas, Godfrey, Dale I, Smyth, Mark J
Format Journal Article
LanguageEnglish
Published United States The Rockefeller University Press 04.08.2003
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The molecular basis of thymocyte negative selection, which plays a critical role in establishing and maintaining immunological tolerance, is not yet resolved. In particular, the importance of the death receptor subgroup of the tumor necrosis factor (TNF)-family has been the subject of many investigations, with equivocal results. A recent report suggested that TRAIL was a critical factor in this process, a result that does not fit well with previous studies that excluded a role for the FADD-caspase 8 pathway, which is essential for TRAIL and Fas ligand (FasL) signaling, in negative selection. We have investigated intrathymic negative selection of TRAIL-deficient thymocytes, using four well-established models, including antibody-mediated TCR/CD3 ligation in vitro, stimulation with endogenous superantigen in vitro and in vivo, and treatment with exogenous superantigen in vitro. We were unable to demonstrate a role for TRAIL signaling in any of these models, suggesting that this pathway is not a critical factor for thymocyte negative selection.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
Address correspondence to M.J. Smyth, Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett St., Melbourne, Victoria 8006, Australia. Phone: 61-3-9656-3728; Fax: 61-3-9656-1411; email: m.smyth@pmci.unimelb.edu.au
ISSN:0022-1007
1540-9538
DOI:10.1084/jem.20030634